Sai Parenteral's Ltd. Share Price

Overview

Sai Parenteral's Ltd. share price is currently ₹451.93, up by ₹6.13 (1.38%) from its previous closing price of ₹445.80. The share price has declined -9.47% over the past month and gained 0% over the past year. The stock's 52-week low and high are ₹393.98 and ₹697.77, respectively. Sai Parenteral's Ltd. has a market capitalisation of ₹ 2,150.00 Cr. The share price was last updated on 23 Oct 2026, 03:30 PM IST.

Sai Parenteral's Ltd.
Sai Parenteral's Ltd.
SAIPARENT
 ₹0.00
 ₹6.13
1.38%
Healthcare
 ₹0.00(%)1D

Updated: 23 Oct 2026, 03:30:00 pm IST

Market Data

Open Price

 ₹445.80

Prev. Close

 ₹445.80
 ₹436.99

Day Low

 ₹468.55

Day High

 ₹393.98

52 Week Low

 ₹697.77

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

120.84

Sector PE

42.08

PB Ratio

4.07

Sector PB

5.48

EPS

3.74

Dividend Yield

0.00

Today's Volume

318.582 K

5 Day Avg. Volume

173.217 K

PEG Ratio

-4.03

Market Cap.

₹ 2,150.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Corporate Actions will be available shortly.

Mutual Fund Ownership

Mutual Fund Holder
Aug 26
Shares held
Sep 26
Shares held
Bandhan Healthcare Fund - Regular Plan - Growth60.83 k
70.83 k
(16.44%)
Bandhan Mid Cap Fund - Regular Plan - Growth32.00 k
52.12 k
(62.86%)
Bandhan Large & Mid Cap Fund - Regular Plan - Growth10.86 k
10.86 k
no change
Motilal Oswal BSE Healthcare ETF-
332
(100%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth-
157
(100%)

About Sai Parenteral's Ltd. 👋

Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organizational products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neruopsychiatry, anti-diabetic, respiratory health, antibiotics, vitamins, minerals and supplements analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the Company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampules, and vials. It manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Pavan Rawat

Pavan Rawat

26 Aug • 2:33 PM · SEBI-Registered Analyst

RAINBOW CHILDREN SHARES FALL ON CFO RESIGNATION

RAINBOW
Shares of Advait Energy Transitions gained 4% after the company received a turnkey contract worth ₹134.63 crore from Madhya Pradesh Power Transmission Co. Ltd. The order involves the design, manufacturing and supply of an Emergency Restoration System suitable for 400kV, 220kV and 132kV voltage-class extra-high-voltage transmission lines, along with all associated accessories. Sai Parenterals shares rose nearly 3% after its Australian subsidiary, Noumed Pharmaceuticals, renewed its OTC Medicines Supply Agreement with one of Australia’s leading multi-billion-dollar pharmacy chains. The renewed agreement includes an expanded product portfolio, a longer tenure and a higher contract value. The deal is estimated at AUD 30 million, or approximately ₹204 crore, over a three-year period and is effective immediately. Rainbow Children’s shares declined nearly 2% after the company announced that Vikas Maheshwari had resigned as Chief Financial Officer (CFO) and Key Managerial Personnel. His resignation will take effect from August 31, 2026, and is attributed to personal reasons. At the sectoral level, the PSU Bank index advanced 1%, while selling pressure was seen in consumer durables, IT and infrastructure stocks. The broader market remained positive, with both the Nifty Midcap and Nifty Smallcap indices gaining around 0.3% each.

See More
Kulneet singh

Kulneet singh

7 Aug • 6:33 PM · SEBI-Registered Analyst

Coal India Expands Beyond Coal with Odisha Iron Ore Block Win

State-owned Coal India Ltd. (CIL) has emerged as the preferred bidder for the Gadadharpur Iron Ore Block in Odisha, marking a significant step in the company's strategy to diversify beyond coal mining. The move is aimed at strengthening its presence in the mining sector and creating new long-term revenue opportunities as India continues to invest heavily in infrastructure, steel production, and manufacturing. The acquisition is strategically important because iron ore is the primary raw material used in steel manufacturing. By entering the iron ore business, Coal India can reduce its dependence on coal while participating in India's growing demand for steel driven by roads, railways, housing, and industrial projects. Investors will closely monitor the company's future mining plans, production targets, and capital allocation strategy. The development is also positive for the broader metals and mining sector. As infrastructure spending continues to rise, demand for iron ore and steel is expected to remain strong, benefiting companies involved in mining, steel production, and mineral logistics. Learning Outcome: Diversification helps companies reduce dependence on a single business segment and create additional growth opportunities. Investors should evaluate whether new projects complement the company's existing operations and have the potential to improve long-term earnings.

BHARATCOAL
TATASTEEL
SAIL
HINDCOPPER
JSWSTEEL
#STEELSECTOR #MARKETUPDATE #STOCKMARKET #FUNDAMENTALANALYSIS #INVESTING

See More
Prachi Mehta

Prachi Mehta

2 Jul • 12:10 PM · SEBI-Registered Analyst

Stocks in news today

HEROMOTOCO
has reached a pivotal milestone in its nation-building mission with the Foundation Stone Laying Ceremony for its second Global Parts Centre (GPC) in Tirupati, Andhra Pradesh. This landmark facility, representing a significant investment of over Rs 750 crore, serves as the foundation of an expansive Rs 3,200 crore plus investment roadmap. The investment is aimed at transforming Tirupati into a world-class manufacturing and electric mobility hub, while strengthening Hero MotoCorp’s global supply chain and reinforcing India’s position in the automotive and EV ecosystem. Sai Parenterals’ Australian subsidiary -- Noumed Pharmaceuticals has successfully renewed its long-term exclusive OTC Medicines Supply Agreement with one of Australia's leading, multi-billion-dollar pharmacy chains with an expanded product portfolio, a longer agreement tenure, and a significantly higher agreement value - reflecting a trusted customer relationship. The renewed agreement is valued at AUD 202 Million (approximately Rs 1300 crore) for the term - translating to about AUD 27 Million per annum - to be executed over an extended term of 7 and half years-- with a further 3-year extension option upon mutual consent. Exato Technologies has received an export order from a global entity for the provision of software licenses. The value of the aforesaid order is $479,375, exclusive of applicable taxes, duties, levies and other government-imposed charges. The receipt of this order reinforces the company’s growing presence in global markets and reflects its continued focus on delivering customer experience (CX) technology solutions to global customers.

See More
Pankaj pawar

Pankaj pawar

1 Jul • 5:07 PM · SEBI-Registered Analyst

BPCL

### Stocks in Focus – Tomorrow **

BPCL
** – A BPCL executive stated that **biofuels are expected to complement, not replace, fossil fuels until around 2040**, highlighting continued long-term demand for conventional fuels while supporting a gradual energy transition. *(Neutral)* **
SAIPARENT
** – Subsidiary **Noumed** signed a **₹1,300 crore OTC pharmaceutical supply agreement in Australia**, significantly strengthening export visibility and international business growth. *(Strongly Positive)* **
V2RETAIL
** – V2 Retail reported **Q1 FY27 revenue of ₹997 crore**, up **58% YoY**, with **7.5% same-store sales growth (SSSG)**. The company added **57 new stores**, expanding its network to **381 stores**, reflecting robust growth momentum. *(Strongly Positive)* **
NMDC
** – NMDC reported **June iron ore production of 5.15 MT (+44% YoY)** and **sales of 3.98 MT (+11% YoY)**. For **Q1 FY27**, production stood at **15.10 MT** and sales at **11.75 MT**, indicating strong operational performance. *(Positive)*

See More
Nikita (SEBI RA)

Nikita (SEBI RA)

17 Apr • 12:12 PM · SEBI-Registered Analyst

“Why Strong Moves Are Supported by Consistent Participation”

A sustainable move needs continuous involvement from market participants. Key signs: Stable or increasing volume Follow-through after each move Limited counter-pressure Learning: Consistency in participation sustains momentum.

SAIPARENT

See More
THREETREND RESEARCH

THREETREND RESEARCH

27 Jan • 10:46 AM · SEBI-Registered Analyst

SEBI GREEN SIGNAL FOR IPOs 🚦 📌 List of IPOs cleared by SEBI: 1️⃣ Jay Jagdamba Limited 2️⃣ Transline Technologies Limited 3️⃣ UKB Electronics Limited 4️⃣ CMR Green Technologies Limited 5️⃣ Medicap Healthcare Limited 6️⃣ Purple Style Labs Limited 7️⃣ Oswal Cables Limited 8️⃣ BVG India Limited 9️⃣ Pride Hotels Limited 🔟 Sai Parenteral’s Limited 1️⃣1️⃣ Commtel Networks Limited 1️⃣2️⃣ Hella Infra Market Ltd. 1️⃣3️⃣ Sify Infinit Spaces Limited

CDSL

See More

News & Events

Frequently Asked Questions

What is the share price of Sai Parenteral's Ltd.?

What is the market cap of Sai Parenteral's Ltd.?

Should I buy Sai Parenteral's Ltd. stock now?

What is the 52 week high and low of Sai Parenteral's Ltd.?

Is the Sai Parenteral's Ltd. stock good to buy?

Is Sai Parenteral's Ltd. a good buy for the long term?

Is Sai Parenteral's Ltd. overvalued or undervalued?

What is the PE and PB ratio of Sai Parenteral's Ltd.?

Start Now